Financial Performance - Operating revenue for Q1 2024 was RMB 2,474,697,457.66, a decrease of 6.25% compared to RMB 2,639,665,769.78 in Q1 2023[2] - Net profit attributable to shareholders for Q1 2024 was RMB 141,879,437.62, down 6.41% from RMB 151,603,818.36 in Q1 2023[2] - Basic earnings per share for Q1 2024 were RMB 0.21, a decrease of 8.70% from RMB 0.23 in Q1 2023[3] - The total profit for Q1 2024 was RMB 168,771,522.02, compared to RMB 184,919,311.15 in Q1 2023, showing a decline in profitability[4] - Net profit attributable to the parent company was approximately $141.88 million, a decrease from $151.60 million in the previous period[5] - Total comprehensive income attributable to the parent company was approximately $142.69 million, compared to $159.49 million previously[5] - Basic earnings per share were $0.21, down from $0.23 in the prior period[5] - Total comprehensive income for the period was approximately $146.08 million, compared to $161.72 million previously[5] - Other comprehensive income after tax attributable to the parent company was approximately $807,373.60, down from $7.89 million previously[5] - The company reported a decrease in foreign currency translation adjustments, with a loss of approximately $(69,418.40)[5] Cash Flow and Assets - Net cash flow from operating activities improved significantly to RMB 38,063,364.43, compared to a negative RMB 183,742,803.27 in the same period last year, representing a 120.72% increase[2] - Total assets as of March 31, 2024, were RMB 8,467,977,386.18, reflecting a 2.19% increase from RMB 8,286,166,330.90 at the end of 2023[3] - Net assets attributable to shareholders increased by 4.65% to RMB 4,764,918,585.13 from RMB 4,553,103,869.56 at the end of 2023[3] Research and Development - Research and development expenses for Q1 2024 were RMB 141,905,763.44, compared to RMB 112,119,587.26 in Q1 2023, indicating a focus on innovation[4] Strategic Initiatives - The company plans to continue its market expansion and enhance product development strategies in the upcoming quarters[1] - The company continues to focus on strategic initiatives to enhance operational efficiency and market presence[5] Governance and Compliance - The board approved changes to accounting policies effective January 1, 2024, with no significant impact on the financial statements[6] - The company is committed to adhering to the new accounting standards as outlined by the Ministry of Finance[6] - The board of directors consists of a mix of executive and independent non-executive members, ensuring diverse governance[7] Profitability Metrics - The company reported a gross profit margin of approximately 5.89% for Q1 2024, down from 6.81% in Q1 2023[4]
山东新华制药股份(00719) - 2024 Q1 - 季度业绩